This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Consecutive patients admitted to the PICU in the daytime were screened for possible enrolment in the study. An interim analysis revealed no significant differences between the study groups in terms of the primary outcome variable, and a revised power calculation indicated that a sample size of several hundred patients would be required to detect any significant difference. The trial was halted as a result of the interim analysis. The authors reported that the age of the patients recruited into the study raged from 34 months to 19 years. The inclusion of patients older than 18 years of age may be inappropriate given that the clinical study question addressed treatment in children.
In total, 336 children were admitted to the PICU in the study period. Of these, 168 were admitted during the night and were excluded, while 110 either failed to meet the inclusion criteria (80) or met the exclusion criteria (30). Fifty-nine patients who met the inclusion criteria were screened for possible enrolment in the study, 19 of whose parents refused consent for the study. The final study sample comprised 40 patients, of which 13 were randomised to theophylline, 16 were randomised to terbutaline, and 11 were randomised to receive both study drugs.
Study design
The study was a single-centre, randomised controlled trial. Patients were randomised using a sealed envelope technique. The patients were followed up until the end of the clinical episode, and there was no loss to follow-up. Hospital staff and study investigators were blinded to the treatment. Intravenous saline was used as a dummy to ensure that all patients received the same amount of intravenous fluids.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The primary health outcome was the change in CAS over time, as assessed by study investigators. The group randomised to receive theophylline and terbutaline had significantly higher Paediatric Risk of Mortality (PRISM) scores than the other groups, (p=0.006), and significantly higher serum glucose levels than the group randomised to theophylline, (p=0.005). A lower percentage of children in the terbutaline group received adjunctive medication than in the other two groups.
Effectiveness results
There were no significant differences between the groups in terms of improvement in CAS.
There were significantly higher median levels of nausea and tremors in the group randomised to theophylline and terbutaline compared with the group randomised to terbutaline, (p<0.05).
Clinical conclusions
The authors concluded that theophylline was as effective as terbutaline in treating critically ill children with status asthmaticus.
Measure of benefits used in the economic analysis
No summary measure of health benefit was used in the economic analysis. The authors assumed that the clinical effectiveness results were equal on the basis of the primary outcome measure, and conducted a cost-minimisation analysis.
Direct costs
The resource use quantities were not reported separately from the costs. The study recorded the direct costs of the study medication to the hospital, and also the additional costs of laboratory tests for theophylline levels in the group randomised to receive theophylline alone. The source of the direct cost data were the hospital charges for the patients in the study, while unit costs were based on the average wholesale price of the study medications. Discounting was not relevant given the short follow-up period. The study reported the median costs. The price year was 2003.
